SCHEMBL3579778

SCHEMBL3579778

CC(=O)NCC1CN(c2ccc(N3CCC4(CC3)COCCO4)c(F)c2)C(=O)O1

nearest known ligand 0.77

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.77
SDHA P31040 2/20 0.77
MAOB P27338 8/20 0.76
MAOA P21397 5/20 0.76
LMNA P02545 1/20 0.76
CALML3 P27482 1/20 0.76
F10 P00742 7/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579773 1.00 PTGS1 (0.77) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3582441 0.97 PTGS1 (0.78) PTGS1SDHAMAOBMAOALMNA
SCHEMBL13314689 0.95 PTGS1 (0.80) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3582444 0.93 MAOB (0.79) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3582438 0.93 MAOB (0.79) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3579122 0.93 MAOB (0.75) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3579120 0.93 MAOB (0.75) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3570466 0.93 MAOB (0.78) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3198676 0.93 MAOB (0.78) PTGS1SDHAMAOBMAOALMNA
SCHEMBL3570464 0.93 MAOB (0.78) PTGS1SDHAMAOBMAOALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP claimed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US claimed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO claimed
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED 2010-06-10 US disclosed
US-7687627-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2010-03-30 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY GMPS, MPO, ARG1 PTGS1 170/4885SDHA 1907/4885MAOB 2975/4885
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy GMPS, MPO, ARG1 PTGS1 170/4885SDHA 1907/4885MAOB 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.